Photoswitchable Stat3 inhibitors: design, synthesis and anticancer activity study on 2D and 3D breast cancer cell cultures

Abstract

Stat3 protein is known to be hyperactive in many human cancer cells, including leukaemia, lymphoma, breast, ovarian, lung, and prostate cancer cells. The treatment of most of these cancer types relies on chemotherapy, which encounters various side effects owing to off-target effects of the drugs. Photopharmacology promises to eliminate such off-target effects with the use of photoswitchable drugs. Based on a potent Stat3 inhibitor, in this study, we developed two azobenzene-based photoswitchable inhibitors 2 and 3. Ambient light-exposed compound 2 contained 90% trans isomer, which upon irradiation with a 365 nm light, isomerized to 81% cis isomer, that showed t1/2 of >38 h at 37 °C. Back-irradiation of the cis-enriched PSS with a 475 nm light yielded 79% trans-enriched PSS. Interestingly, cis- and trans-enriched PSSs showed 1.3–1.5 times higher anticancer potencies against the MDA-MB-231 breast cancer cell line than the parent Stat3 inhibitor 1, except the trans-enriched PSS of 2 (1.2 times less activity). In the 2D cell culture study, the cis-enriched PSS of 2 (IC50 of 4.8 ± 0.5 μM) was found to be 1.7-fold more potent than its trans-enriched PSS. Notably, the 3D cell spheroid culture study displayed a better photopharmacological response, in which the cis-enriched PSS induced 2.5-fold higher spheroid growth inhibition than the trans-enriched PSS. Cell cycle analysis demonstrated the arrest of the cell cycle in the G1 phase, which occurred more efficiently using the cis isomer than the trans isomer. An immunoblot assay confirmed the inhibition of Stat3 activation. These experimental results agreed with the in silico docking performed on the SH2 domain of Stat3.

Graphical abstract: Photoswitchable Stat3 inhibitors: design, synthesis and anticancer activity study on 2D and 3D breast cancer cell cultures

Supplementary files

Transparent peer review

To support increased transparency, we offer authors the option to publish the peer review history alongside their article.

View this article’s peer review history

Article information

Article type
Research Article
Submitted
29 May 2025
Accepted
03 Jun 2025
First published
06 Jun 2025

RSC Med. Chem., 2025, Advance Article

Photoswitchable Stat3 inhibitors: design, synthesis and anticancer activity study on 2D and 3D breast cancer cell cultures

S. Bera, S. Bose, N. Paul, S. Bhunia, A. Das and S. Samanta, RSC Med. Chem., 2025, Advance Article , DOI: 10.1039/D5MD00490J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements